glp-1 deficiency Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH 9 Nutrient Deficiencies You May

Bupropion and naltrexone (Contrave): An opioid blocker combined with an antidepressant that can help reduce emotional eating

Market expansion is being supported by the growing recognition of obesity as a chronic disease requiring pharmacological intervention and the compelling clinical evidence demonstrating substantial cardiovascular risk reduction in treated populations

Transdermal Natural GLP-1 Dietary Supplements Violate Law and Place Patients at Risk

Graphical Abstract Similar content being viewed by others Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), with a steady upward trend in prevalence estimates from 25.3% in 19902006 to 38.2% in 20162019 [1], has become a leading cause of chronic liver disease worldwide [2,3,4], increasing the risk of both hepatic and extrahepatic complications, such as cardiovascular and chronic kidney diseases [5, 6]